Skip Links

Development Pipeline

at 28 January 2010

  Estimated filing date
Therapy area Compound   Mechanism   Areas under investigation   MAA NDA
Phase I projects
Cardiovascular AZD6482   PI3K-beta inhibitor   thrombosis      
  AZD4017   11BHSD inhibitor   diabetes/obesity      
  AZD6714   GK activator   diabetes      
  AZD8329   11BHSD inhibitor   diabetes/obesity      
  AZD7687   diacylglycerol acyl transferase -1 inhibitor   diabetes/obesity      
Gastrointestinal AZD2066   metabotropic glutamate receptor 5 antagonist   GERD      
  AZD2516   metabotropic glutamate receptor 5 antagonist   GERD      
Infection MEDI-534   RSV/PIV-3 vaccine   RSV/PIV prophylaxis      
  MEDI-560   PIV-3 vaccine   intranasal immunisation      
  MEDI-550   pandemic influenza virus vaccine   pandemic influenza vaccine      
  MEDI-557   YTE - extended half-life RSV MAb   RSV prophylaxis      
  MEDI-559   RSV vaccine   RSV prophylaxis      
  AZD5847   Oxazolidinone anti-bacterial inhibitor   tuberculosis      
  AZD9742   BTGT4 IV   MRSA      
  CEF1041#   beta lactamase inhibitor/cephalosporin   MRSA      
Neuroscience AZD3241   myeloperoxidase (MPO) inhibitor   Parkinson's disease      
  AZD6280   GABA receptor subtype partial agonist   anxiety      
  AZD2516   metabotropic glutamate receptor 5 antagonist   chronic neuropathic pain      
  AZD3043#   GABA-A receptor modulator   short acting sedative and anaesthetic      
  AZD8418   glutamatergic modulator   schizophrenia      
  AZD2423   chemokine antagonist   chronic neuropathic pain      
Oncology AZD4769   EGFR tyrosine kinase inhibitor   solid tumours      
  AZD8931   erbB kinase inhibitor   solid tumours      
  AZD7762   CHK1 kinase inhibitor   solid tumours      
  AZD8330# (ARRY-424704)   MEK inhibitor   solid tumours      
  CAT-8015   recombinant immunotoxin   haematological malignancies      
  AZD8055   TOR kinase inhibitor   range of tumours      
  MEDI-573   IGF   solid tumours      
  MEDI-575   PDGFR-alpha   solid tumours      
  AZD1480   JAK2 inhibitor   myeloproliferative diseases /solid tumours      
  AZD4547   FGFR tyrosine kinase inhibitor   solid tumours      
  MEDI-547#   EphA2 conjugate   solid tumours      
  AZD2014   MTOR inhibitor   solid tumours      
  AZD6244 (ARRY-142886)/MK2206#   MEK/AKT inhibitor   solid tumours      
Respiratory & Inflammation CAM-3001#   anti-GM-CSFR   rheumatoid arthritis      
AZD8566   CCR5   COPD      
  AZD8075   CRTh2 antagonist   asthma/COPD      
  AZD5985   CRTh2 antagonist   asthma/COPD      
  AZD2551   protease inhibitor   COPD      
  AZD5423   iSEGRA   COPD      
  AZD5122   CXCR2   COPD      
  AZD8683   Muscarinic antagonist   COPD      
  AZD5069   CXCR2   COPD      
  MEDI-546#   anti-IFNaR MAb   scleroderma      
1
Subject to expiry or termination of the applicable waiting period under the US Hart-Scott-Rodino Antitrust Improvements Act.
#
Partnered product.
  Estimated filing date
Therapy area Compound   Mechanism   Areas under investigation   MAA NDA
Phase II projects
Cardiovascular AZD0837   direct thrombin inhibitor   thrombosis      
  AZD6370   GK activator   diabetes      
  AZD1656   GK activator   diabetes   2015 2015
Gastrointestinal Lesogaberan (AZD3355)   GABAB agonist   GERD   2013 2013
  AZD1386   vanilloid receptor antagonist   GERD      
Infection CytoFab™#   anti-TNF-alpha polyclonal antibody   severe sepsis   2014 2014
  AZD7295   NS 5A inhibitor   hepatitis C   2015 2015
  MEDI-3250   flu vaccine (quadravalent)   seasonal influenza      
  CAZ1041#   beta lactamase inhibitor/cephalosporin   serious infections   2012 n/a
Neuroscience AZD3480#   Alpha4/beta2 neuronal nicotinic receptor agonist   ADHD      
  AZD6765   NMDA receptor antagonist   MDD   2013 2013
  AZD2327   enkephalinergic receptor modulator   anxiety and depression      
  AZD2066   metabotropic glutamate receptor 5 antagonist   chronic neuropathic pain      
  AZD8529   glutamatergic modulator   schizophrenia      
  NKTR-118#   oral peripherally-acting opioid antagonist   opioid-induced constipation   2013 2013
  TC-5214#   nicotinic ion channel blocker   MDD   2014 2012
  TC-5619#   Alpha7 neuronal nicotinic receptor agonist   cognitive disorders in schizophrenia      
  AZD7268   enkephalinergic receptor modulator   depression/anxiety      
  AZD1446#   Alpha4/beta2 neuronal nicotinic receptor agonist   Alzheimer's disease/ADHD      
Oncology Recentin   VEGFR tyrosine kinase inhibitor   NSCLC   2013 2013
  AZD6244# (ARRY-142886)   MEK inhibitor   solid tumours   2014 2014
  Olaparib   PARP inhibitor   gBRCA breast cancer   2012 2012
  Olaparib   PARP inhibitor   serious ovarian cancer   2014 2014
  AZD1152   aurora kinase inhibitor   haematological malignancies   2012 2012
Respiratory & Inflammation AZD1981   CRTh2 receptor antagonist   asthma/COPD      
MEDI-528#   anti-IL-9 antibody   asthma      
  CAT-354   anti-IL-13 antibody   asthma      
  AZD9668   neutrophil elastase inhibitor   COPD   2014 2014
  AZD1236   matrix metallo-proteinase inhibitor   COPD      
  AZD3199   iLABA   asthma/COPD      
  MEDI-563#   anti-IL-5R antibody   asthma      
  MEDI-545#   anti-IFN-alpha antibody   SLE, myositis      
  AZD9164   LAMA   COPD      
  AZD8848   Toll-like receptor-7 agonist   asthma      
  Estimated filing date
Therapy area Compound   Mechanism   Areas under investigation   MAA NDA
Phase II line extensions
Infection Motavizumab#   humanised MAb binding to RSV F protein   early and late treatment of RSV in paediatrics >1 yr     2015
  Estimated filing date
Therapy area Compound   Mechanism   Areas under investigation   MAA NDA
Phase III projects
Cardiovascular Onglyza™#   DPP-4 inhibitor   diabetes   Launched Launched
  Brilinta/Brilique   ADP receptor antagonist   arterial thrombosis   Filed Filed
  Certriad#   statin + fibrate fixed combination   dyslipidaemia     Filed
  Dapagliflozin#   SGLT2 inhibitor   diabetes   Q4 2010 Q4 20102
Infection Motavizumab#   humanised MAb binding to RSV F protein   RSV prevention   Q4 2010 Filed
  Ceftaroline#   affinity to penicillin-binding proteins   pneumonia/skin infections   Q3 2010 n/a
Neuroscience Vimovo#   naproxen + esomeprazole   signs and symptoms of OA, RA and ankylosing spondylitis   Filed Filed
Oncology Zactima   VEGFR/EGFR tyrosine kinase inhibitor with RET kinase activity   medullary thyroid cancer - orphan   Q3 2010 Q3 2010
  Recentin   VEGFR tyrosine kinase inhibitor   CRC   Q4 2010 Q4 2010
  Recentin   VEGFR tyrosine kinase inhibitor   recurrent glioblastoma - orphan   Q4 2010 Q4 2010
  Zibotentan (ZD4054)   endothelin A receptor antagonist   castrate resistant prostate cancer   H1 2011 H1 2011
1
Subject to expiry or termination of the applicable waiting period under the US Hart-Scott-Rodino Antitrust Improvements Act.
2
Timing subject to CV event rate.
#
Partnered product.
  Estimated filing date
Therapy area Compound   Mechanism   Areas under investigation   MAA NDA
Phase III line extensions
Cardiovascular Crestor   statin   outcomes in subjects with elevated CRP   Filed Filed
  Onglyza™/ metformin FDC#   DPP-4 inhibitor + biguanide FDC   diabetes   Q3 2010 Filed
  Dapagliflozin/metformin FDC#   SGLT2 inhibitor + biguanide FDC   diabetes   H2 2011 H2 2011
Gastrointestinal Nexium   proton pump inhibitor   peptic ulcer bleeding   Launched Filed
  Axanum   proton pump inhibitor + low dose aspirin FDC   low dose aspirin associated peptic ulcer   Q3 20103 Filed
Infection FluMist   live, attenuated, intranasal influenza virus vaccine   influenza   Filed Launched
  MEDI-3414   H1N1 influenza   pandemic flu prevention     Launched
Neuroscience Seroquel   D2/5HT2 antagonist   bipolar maintenance   Launched Launched
  Seroquel XR   D2/5HT2 antagonist   MDD   Filed Approved
  Seroquel XR   D2/5HT2 antagonist   GAD   Filed Filed
Oncology Iressa   EGFR tyrosine kinase inhibitor   NSCLC   Launched TBD
  Faslodex   oestrogen receptor antagonist   1st line advanced breast cancer      
  Faslodex   oestrogen receptor antagonist   high dose (500mg) 2nd line advanced breast cancer   Filed Filed
3
Previously, submission was indication only. Now covers fixed-dose combination.
#
Partnered product.
Therapy area Compound   Areas under investigation
Discontinued projects
Cardiovascular AZD1305   arrhythmias
Infection AZD9639   RSV treatment
  CMV Vaccine   cytomegalovirus
Neuroscience AZD5904   multiple sclerosis
  AZD6088   chronic neuropathic pain
  AZD1386   chronic neuropathic pain
  AZD7325   anxiety
  AZD4694   Alzheimer's disease PET diagnostic
  AZD1940   nociceptive and neuropathic pain
  AZD2624   schizophrenia
Oncology Saracatinib   solid tumours
  Zactima   NSCLC
  AZD6918   solid tumours
  MEDI-538   leukaemia/lymphoma
  AZD4877   haematological malignancies
Respiratory & Inflammation AZD9056   RA
  AZD5672   RA

During 2009, AstraZeneca reclassified into pre-clinical development, the EBV vaccine which appeared in Phase II of the Development Pipeline table in the 2008 Annual Report and Form 20-F Information. AstraZeneca has out-licensed the development of the pneumococcal vaccine which appeared in Phase I of the Development Pipeline table in the 2008 Annual Report and Form 20-F Information.

Therapy area Compound   Areas under investigation
Discontinued line extensions
Oncology Faslodex   adjuvant
Respiratory & Inflammation Symbicort pMDI EU   asthma
  Symbicort pMDI EU   COPD
  Unit Dose Budesonide   asthma

As disclosure of compound information is balanced by the business need to maintain confidentiality, information in relation to some compounds listed here has not been disclosed at this time.

Compounds in development are displayed by phase.

AstraZeneca
at a glance

"We are focused on the discovery, development and commercialisation of prescription medicines for six important areas of healthcare."

Find out more

Quick
links

Download
Report

AstraZeneca Annual Report and Form 20-F Information 2009

English (PDF 5.8Mb)
Swedish (PDF 3.3Mb)

Visit the Download centre